Yuxian Bai
About
Yuxian Bai is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery.
According to data from OpenAlex, Yuxian Bai has authored 187 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 125 papers in Oncology, 104 papers in Pulmonary and Respiratory Medicine and 50 papers in Surgery. Recurrent topics in Yuxian Bai's work include Gastric Cancer Management and Outcomes (63 papers), Colorectal Cancer Treatments and Studies (59 papers) and Cancer Immunotherapy and Biomarkers (38 papers). Yuxian Bai is often cited by papers focused on Gastric Cancer Management and Outcomes (63 papers), Colorectal Cancer Treatments and Studies (59 papers) and Cancer Immunotherapy and Biomarkers (38 papers). Yuxian Bai collaborates with scholars based in China, United States and South Korea. Yuxian Bai's co-authors include Shukui Qin, Jianming Xu, Ying Cheng, Tianshu Liu, Yanjing Li, Jianping Xiong, Zhenggang Ren, Hongming Pan, Rui‐Hua Xu and Shukui Qin and has published in prestigious journals such as Nature, The Lancet and The Journal of Experimental Medicine.
In The Last Decade
Yuxian Bai
177 papers receiving 5.9k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Yuxian Bai China | 37 | 3.2k | 2.3k | 1.5k | 1.4k | 1.2k | 187 | 6.0k | ||
| Allen Lee Cohn United States | 38 | 4.7k 1.5× | 2.4k 1.0× | 1.5k 1.0× | 1.2k 0.8× | 875 0.7× | 159 | 6.9k | ||
| Alessandro Rizzo Italy | 57 | 3.3k 1.0× | 2.6k 1.1× | 1.6k 1.1× | 770 0.5× | 2.0k 1.7× | 220 | 6.5k | ||
| Young Suk Park South Korea | 41 | 4.0k 1.2× | 2.3k 1.0× | 1.3k 0.9× | 440 0.3× | 1.9k 1.6× | 227 | 6.3k | ||
| Francesco Graziano Italy | 43 | 3.3k 1.0× | 1.8k 0.8× | 1.8k 1.2× | 722 0.5× | 1.3k 1.1× | 163 | 5.8k | ||
| Vincenzo Catalano Italy | 40 | 3.1k 1.0× | 1.6k 0.7× | 1.4k 0.9× | 667 0.5× | 1.2k 1.0× | 124 | 5.1k | ||
| Baki Topal Belgium | 40 | 2.5k 0.8× | 2.0k 0.9× | 1.4k 1.0× | 843 0.6× | 2.3k 1.9× | 100 | 5.6k | ||
| Ferry A.L.M. Eskens Netherlands | 43 | 2.9k 0.9× | 1.5k 0.6× | 2.6k 1.7× | 694 0.5× | 592 0.5× | 161 | 6.4k | ||
| Javier Sastre Spain | 39 | 4.8k 1.5× | 1.9k 0.8× | 988 0.7× | 1.5k 1.0× | 1.2k 1.0× | 177 | 6.7k | ||
| Alain Hendlisz Belgium | 33 | 5.2k 1.6× | 2.0k 0.9× | 1.1k 0.7× | 1.2k 0.8× | 1.3k 1.1× | 209 | 7.1k | ||
| Piercarlo Saletti Switzerland | 29 | 4.3k 1.3× | 2.1k 0.9× | 1.0k 0.7× | 753 0.5× | 941 0.8× | 74 | 5.5k |
Countries citing papers authored by Yuxian Bai
Since
Specialization
Citations
This map shows the geographic impact of Yuxian Bai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuxian Bai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuxian Bai more than expected).
Fields of papers citing papers by Yuxian Bai
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Yuxian Bai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuxian Bai. The network helps show where Yuxian Bai may publish in the future.
Co-authorship network of co-authors of Yuxian Bai
This figure shows the co-authorship network connecting the top 25 collaborators of Yuxian Bai. A scholar is included among the top collaborators of Yuxian Bai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuxian Bai. Yuxian Bai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Lin, Xia, Yuxian Bai, Xiaowen Liang, et al.. (2025). Effect of surgery on overall survival and cancer-specific survival in patients with primary HCC: A study based on PSM in the SEER cohort. Medicine. 104(8). e41521–e41521.
2.
Rha, Sun Young, Lucjan Wyrwicz, Yuxian Bai, et al.. (2024). Pembrolizumab (pembro) + chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Updated results from the KEYNOTE-859 study.. Journal of Clinical Oncology. 42(16_suppl). 4045–4045.
3.
Chan, Stephen L., Zhenggang Ren, Yuxian Bai, et al.. (2024). Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study.. Journal of Clinical Oncology. 42(16_suppl). 4110–4110.
4.
Qiu, Miao‐Zhen, Yuxian Bai, Jufeng Wang, et al.. (2024). Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer. Signal Transduction and Targeted Therapy. 9(1). 349–349.
5.
Cruz‐Correa, Marcia, D-Y. Oh, Ken Kato, et al.. (2024). 1437P Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in HER2-negative advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJC): RATIONALE-305 study minimum 3-year survival follow-up. Annals of Oncology. 35. S893–S894.
6.
Qin, Shukui, Elizabeth Li, Baocai Xing, et al.. (2023). 98P Efficacy and safety of durvalumab plus gemcitabine and cisplatin in Chinese participants with advanced biliary tract cancer: Extension cohort of the phase III, randomised, double-blind, placebo-controlled, global TOPAZ-1 study. Annals of Oncology. 34. S216–S217.
7.
Wei, Xiaoting, Jialin Li, Hui Yuan, et al.. (2023). 1519P Fruquintinib plus sintilimab in patients (pts) with either treatment-naïve or previously treated advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results from a multicenter, single-arm phase II study. Annals of Oncology. 34. S856–S856.
8.
Wyrwicz, Lucjan, Do‐Youn Oh, Yuxian Bai, et al.. (2023). O-3 Additional data from the KEYNOTE-859 study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer. Annals of Oncology. 34. S181–S181.
9.
Oh, D-Y., Ken Kato, Tobias Arkenau, et al.. (2023). LBA80 Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study. Annals of Oncology. 34. S1320–S1321.
10.
Zhu, Andrew X., Farshid Dayyani, Chia‐Jui Yen, et al.. (2022). Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma. Clinical Cancer Research. 28(16). 3537–3545.
11.
Shao, Guoliang, Xu Zhu, Weijia Fang, et al.. (2022). Phase 2 Study of the PD-1 Inhibitor Serplulimab plus the Bevacizumab Biosimilar HLX04 in Patients with Previously Treated Advanced Hepatocellular Carcinoma. Liver Cancer. 12(2). 116–128.
12.
Qin, Shukui, Zhendong Chen, Weijia Fang, et al.. (2022). Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial. Journal of Clinical Oncology. 41(7). 1434–1443.
13.
Janjigian, Yelena Y., Akihito Kawazoe, Patricio Yañez, et al.. (2021). The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 600(7890). 727–730.
14.
Xu, Jianming, Yuxian Bai, Nong Xu, et al.. (2020). Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma. Clinical Cancer Research. 26(17). 4542–4550.
15.
Gan, Junqing, Shumin Li, Yu Meng, et al.. (2020). The influence of photodynamic therapy on the Warburg effect in esophageal cancer cells. Lasers in Medical Science. 35(8). 1741–1750.
16.
Li, Shumin, Peng Huang, Junqing Gan, et al.. (2019). Dihydroartemisinin represses esophageal cancer glycolysis by down-regulating pyruvate kinase M2. European Journal of Pharmacology. 854. 232–239.
17.
Huang, Jing, Jing Huang, Binghe Xu, et al.. (2019). Irinotecan plus S‐1 versus S‐1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open‐labeled phase 3 trial. Cancer Communications. 39(1). 16–16.
18.
Liu, Tianshu, Yanru Qin, Jin Li, et al.. (2019). Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2‐positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial. Cancer Communications. 39(1). 38–38.
19.
Xu, Rui‐Hua, Jin Li, Yuxian Bai, et al.. (2017). Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. Journal of Hematology & Oncology. 10(1).
20.
Xu, Yingjie, Hong Sui, & Yuxian Bai. (2012). 22. Expression and clinical significance of TF and Her-2 in gastric carcinoma.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Allen Lee Cohn Breakdown of academic impact, for papers by Alessandro Rizzo Breakdown of academic impact, for papers by Young Suk Park Breakdown of academic impact, for papers by Francesco Graziano Breakdown of academic impact, for papers by Vincenzo Catalano Breakdown of academic impact, for papers by Baki Topal Breakdown of academic impact, for papers by Ferry A.L.M. Eskens Breakdown of academic impact, for papers by Javier Sastre Breakdown of academic impact, for papers by Alain Hendlisz Breakdown of academic impact, for papers by Piercarlo Saletti